Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 3, 1998, Pages 583-588

  Drabick, Joseph J ^a,c   Bhattacharjee, Apurba K ^a   Hoover, David L ^a   Siber, George E ^b   Morales, Vivian E ^a   Young, Lynnette D ^a   Brown, Scott L ^c   Cross, Alan S ^d  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b PFIZER INC   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; ANTIENDOTOXIN REAGENT; ENDOTOXIN; IMMUNOGLOBULIN G; POLYMYXIN B; REAGENT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBODY DETECTION; ARTICLE; BACTERICIDAL ACTIVITY; COVALENT BOND; DOSE RESPONSE; DRUG BINDING; DRUG CONJUGATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEPHROTOXICITY; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0031894834     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.3.583     Document Type: Article

References (34)

1. Alving, C. R. 1995. Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. Ann. N. Y. Acad. Sci. 754:143-152.
2. Appelmelk, B. J., D. Su, A. Marian, J. J. Verweij-van Vught, B. G. Thijs, and D. M. MacLaren. 1992. Polymyxin B-horseradish peroxidase conjugates as tools in endotoxin research. Anal. Biochem. 207:311-316.
3. Bhattacharjee, A. K., S. M. Opal, J. E. Palardy, J. J. Drabick, H. Collins, R. Taylor, A. Cotton, and A. S. Cross. 1996. Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis. J. Infect. Dis. 173:1157-1163.
4. Bone, R. C. 1991. The pathogenesis of sepsis. Ann. Intern. Med. 115:457-469.
5. Borrebaeck, C. A. K. (ed.). 1992. Antibody engineering: a practical guide. W. H. Freeman and Co., New York, N.Y.
6. Bucklin, S. E., P. Lake, L. Logdberg, and D. C. Morrison. 1995. Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia. Antimicrob. Agents Chemother. 39:1462-1466.
7. Centers for Disease Control. 1990. Increase in national hospital discharge survey rates for septicemia - United States: 1979-1987. Morbid. Mortal. Weekly Rep. 39:31-34.
8. Cohen, J., M. Aslam, C. D. Pusey, and C. J. Ryan. 1987. Protection from endotoxinemia: a rat model of plasmapheresis and specific absorption with polymyxin B. J. Infect. Dis. 155:690-695.
9. Drabick, J., A. Bhattacharjee, W. Williams, G. Siber, and A. S. Cross. 1992. Covalent polymyxin B-starch and polymyxin B-immunoglobulin G conjugates as novel anti-endotoxin reagents. Clin. Res. 40:287A. (Abstract.)
10. Drabick, J. J. 1993. Unpublished data.
11. Fletcher, M. A., M. Kloczewiak, P. M. Loiselle, S. F. Amato, K. M. Black, and H. S. Warren. 1996. TALF peptide-immunoglobulin conjugates that bind lipopolysaccharide. J. Endotoxin Res. 3:49-55.
12. Fletcher, M. A., M. A. Kloczewiak, P. M. Loiselle, M. Ogata, M. W. Vermeulen, E. M. Zanzot, and H. S. Warren. 1997. A novel peptide-IgG conjugate, CAP18(106-138)-IgG, that binds and neutralizes endotoxin and kills gram-negative bacteria. J. Infect. Dis. 175:621-632.
13. Flynn, P. M., J. L. Shenep, D. C. Stokes, D. Fairclough, and W. K. Hildner. 1987. Polymyxin B moderates acidosis and hypotension in established, experimental gram-negative sepsis. J. Infect. Dis. 156:706-712.
14. Galanos, C., M. A. Freudenberg, and W. Reutter. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA 73:5939-5943.
15. Goris, R. J. A. 1993. Sepsis and multiple organ failure: the result of whole body inflammation, p. 161-170. In E. Faist, T. Meakin, and F. W. Schildberg (ed.). Host defense dysfunction in trauma, shock and sepsis. Springer-Verlag, Berlin, Germany.
16. Gough, M., R. E. W. Hancock, and N. M. Kelly. 1996. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect. Immun. 64:4922-4927.
17. Handley, D. ,A. and P. Lake. January 1993. Polymyxin B conjugates. U. S. patent 5,177,059.
18. Hoover, D. L., A. M. Friedlander, L. C. Rogers, I. K. Yoon, R. L. Warren, and A. S. Cross. 1994. Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin 6 by increasing intracellular cyclic AMP. Infect. Immun. 62:4432-4439.
19. Marra, M., C. G. Wilde, J. E. Griffith, J. L. Snable, and R. W. Scott. 1990. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J. Immunol. 144:662-666.
20. Morell, A., and W. Riesen. 1981. Structure, function and catabolism of immunoglobulins, p. 17-26. In U. E. Nydegger (ed.), Immunochemotherapy: a guide to immunoglobulin prophylaxis and therapy. Academic Press, London, United Kingdom.
21. Morrison, D. C., and D. M. Jacobs. 1976. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 13:813-818.
22. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed., vol. 13, no. 25. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
23. Nord, N. M., and P. D. Hoeprich. 1964. Polymyxin B and colistin. A critical comparison. N. Engl. J. Med. 270:1030-1035.
24. Opal, S. M. 1995. Clinical trials of novel therapeutic agents: why did they fail?, p. 425-436. In J. L. Vincent (ed.), Yearbook of intensive care and emergency medicine. Springer-Verlag, Berlin, Germany.
25. Opal, S. M., J. E. Palardy, N. Parejo, P. K. Dubin, J. Pribble, D. Stiles, J.-L. Vincent, and C. J. Fisher, Jr. 1995. Endotoxemia in patients with sepsis syndrome: therapeutic and prognostic implications, abstr. G88, p. 173. In Abstracts of 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
26. Perl, T. M., L. Dvorak, T. Hwant, and R. P. Wenzel. 1995. Long-term survival and function after suspected gram-negative sepsis. JAMA 274:338-345.
27. Raetz, C. R. H., R. J. Ulevitch, S. D. Wright, C. H. Sibley, A. Ding, and C. F. Nathan. 1991. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J. 5:2652-2660.
28. Seale, T. W., and O. M. Rennert. 1992. Mechanisms of antibiotic-induced nephrotoxicity. Ann. Clin. Lab. Sci. 12:1-9.
29. Vaara, M., and T. Vaara. 1981. Outer membrane permeability barrier disruption by polymyxin in polymyxin-susceptible and resistant Salmonella typhimurium. Antimicrob. Agents Chemother. 19:578-583.
30. Wahl, L. M., I. M. Katona, R. L. Wilder, C. C. Winter, B. Haraoui, I. Scher, and S. Wahl. 1984. Isolation of human mononuclear cell subsets by counter flow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte, T-lymphocyte, and monocyte-enriched fractions by flow cytometric analysis. Cell. Immunol. 85:373-378.
31. Warren, H. S., M. L. Glennon, N. Wainwright, S. F. Amato, K. M. Black, S. J. Kirsch, G. R. Riveau, R. I. Whyte, W. M. Zapol, and T. J. Novitsky. 1992. Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor. Infect. Immun. 60:2506-2513.
32. Westphal, O., and K. Jann. 1965. Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Methods Carbohydr. Chem. 5:83-91.
33. Woolson, R. F. 1987. Statistical methods for the analysis of biomedical data, p. 215-221. John Wiley and Sons, New York, N.Y.
34. Ziegler, E. J., H. Douglas, J. E. Sherman, C. E. Davis, and A. I. Braude. 1973. Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-Gal epimerase-deficient mutant. J. Immunol. 111:433-438.